<?xml version="1.0" encoding="UTF-8"?>
<ref id="b8-1040797">
 <label>8.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Eichhorst</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Fink</surname>
    <given-names>AM</given-names>
   </name>
   <name>
    <surname>Bahlo</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial</article-title>. 
  <source>Lancet Oncol</source>. 
  <year>2016</year>;
  <volume>17</volume>(
  <issue>7</issue>):
  <fpage>928</fpage>â€“
  <lpage>942</lpage>.
  <pub-id pub-id-type="pmid">27216274</pub-id>
 </mixed-citation>
</ref>
